Deviation reports did not contain sufficient information to describe the investigations conducted or demonstrate the evidence that supported the proposed root cause.MHRA2016 · p.8Deviation, CAPA, and investigationChapter 1Source file
MHRA · UK
Example deficiencies MHRA published in its GMP inspection deficiency trend reports, all verbatim — 371 in total. 2016 · 2015.
Matching deficiencies 371
Deviation reports did not contain sufficient information to describe the investigations conducted or demonstrate the evidence that supported the proposed root cause.MHRA2016 · p.8Deviation, CAPA, and investigationChapter 1Source file
In some cases there were no formal CAPA raised and in others the CAPA were not adequate. There was no review of repeated deviations which would indicate a trend or failure of CAPAs to resolve the issue.MHRA2016 · p.8Deviation, CAPA, and investigationChapter 1Source file
The site had not established and maintained an effective control system to monitor process and product quality, and had not applied an appropriate level of investigation or fully documented all potential serious incidents, with the objective of determining the root cause and implementing appropriate corrective and preventive action.MHRA2016 · p.8Deviation, CAPA, and investigationChapter 1Source file
There was no requirement to identify the impact of the deviation on the batch.MHRA2016 · p.9Deviation, CAPA, and investigationChapter 1Source file
There was no process to escalate deviations in a timely manner in the event of an issue having the potential to present a patient safety impact.MHRA2016 · p.9Deviation, CAPA, and investigationChapter 1Source file
There was no procedural requirement to consider if the deviation had occurred previously.MHRA2016 · p.9Deviation, CAPA, and investigationChapter 1Source file
There was no requirement to ensure that process, procedural or systems based errors had not been overlooked prior to identifying ‘Personnel Error’ as a root cause.MHRA2016 · p.9Deviation, CAPA, and investigationChapter 1Source file
There was no timeline for completion of the deviations in the procedure (other than ‘in a timely manner’).MHRA2016 · p.9Deviation, CAPA, and investigationChapter 1Source file
The root causes recorded were not always those identified in the procedure.MHRA2016 · p.9Deviation, CAPA, and investigationChapter 1Source file
At least 8 overdue CAPA (ranging from 59 days to 242 days overdue) were observed to have been closed the day before the inspection.MHRA2016 · p.10Deviation, CAPA, and investigationChapter 1Source file
Two overdue CAPA were open at the time of the inspection (186 days and 60 days overdue).MHRA2016 · p.10Deviation, CAPA, and investigationChapter 1Source file
Where134 deviations were raised between November 2015 and February 2016, no CAPA were raised.MHRA2016 · p.10Deviation, CAPA, and investigationChapter 1Source file
Effective monitoring of CAPA was not in place as numerous CAPA with different due dates could be recorded on a single form but only the latest date was tracked.MHRA2016 · p.10Deviation, CAPA, and investigationChapter 1Source file
The review of effectiveness of CAPAs was identified as being part of Management Review, however there was insufficient detail describing this process and the process was not risk based as the Management Review was only carried out once a year.MHRA2016 · p.10Deviation, CAPA, and investigationChapter 1Source file
There was no formal Management review process.MHRA2016 · p.11Quality unit oversightChapter 1Source file
A number of process improvements had been identified across the company yet not logged or tracked in the PQS.MHRA2016 · p.11Quality unit oversightChapter 1Source file
The management team was not seen to be reacting effectively to poor key performance indicators.MHRA2016 · p.11Quality unit oversightChapter 1Source file
Senior management had failed to ensure an effective Quality Management System was in place as evidenced by the fact that a number of the CAPA from the previous MHRA inspection had not been completed on time.MHRA2016 · p.11Deviation, CAPA, and investigationChapter 1Source file
There was no written procedure for the Quality Monthly Meetings attended by the departmental managers to review the effective implementation of the quality system.MHRA2016 · p.11Quality unit oversightChapter 1Source file
The management team failed to ensure an effective implementation of the quality systems and to identify opportunities for continual improvement of components, processes and system itself.MHRA2016 · p.12Material and supplier controlChapter 1Source file
The current reporting method on quality metrics did not sufficiently identify and allow monitoring and assessing the effective implementation of the quality systems. For example, the open and overdue items were not reported for discussion.MHRA2016 · p.12Regulatory reporting and change controlChapter 1Source file
The outstanding quality items reported in the management review meetings were not challenged to identify the root cause for the delay. Risk assessments had not been performed or formally documented to assess the impact on patient safety and the effectiveness of the PQS as a result of choosing to delay addressing the overdue actions.MHRA2016 · p.12Quality unit oversightChapter 1Source file
The management review process was deficient, for example, the meeting minutes stated that all environmental monitoring results were satisfactory; despite there being an obvious adverse trend increase in clean room environmental monitoring results.MHRA2016 · p.13Environmental monitoringChapter 1Source file
The monthly quality system metrics generated do not include the status of supplier audits and do not show site performance over time to allow an effective review of performance changes and to confirm that the quality system is in a state of control.MHRA2016 · p.13Material and supplier controlChapter 1Source file
There was insufficient detail recorded to describe the nature of the change and the actions to be carried out.MHRA2016 · p.14Regulatory reporting and change controlChapter 1Source file
There is no definition of which moderate level change controls would require a risk assessment and regulatory affairs review and which would not.MHRA2016 · p.14Regulatory reporting and change controlChapter 1Source file
There is no post implementation review of the effectiveness of change control actions.MHRA2016 · p.14Regulatory reporting and change controlChapter 1Source file
Changes were implemented outside of the company’s Change Control procedure.MHRA2016 · p.14Regulatory reporting and change controlChapter 1Source file
Procedures for the prospective evaluation of planned changes and their approval prior to implementation taking into account regulatory notification were not robust.MHRA2016 · p.14Regulatory reporting and change controlChapter 1Source file
There was no documented requirement for a post implementation effectiveness check to be performed.MHRA2016 · p.14Regulatory reporting and change controlChapter 1Source file
The PQR procedure did not require a review of the supply chain traceability of active substances taking into account the full supply route and manufacturers (including intermediates).MHRA2016 · p.15Quality unit oversightChapter 1Source file
The completed PQR did not identify that all the relevant technical agreements were in place.MHRA2016 · p.15Quality unit oversightChapter 1Source file
There was no confirmation that the ongoing stability studies showed no adverse trends and would be expected to remain within specification for the proposed shelf life.MHRA2016 · p.15Stability and storageChapter 1Source file
The review of critical parameters did not present data to determine if there was a trend and no comment was made on whether there was a trend.MHRA2016 · p.15Quality unit oversightChapter 1Source file
There was no consideration of the purified water results to determine if the system was performing as required.MHRA2016 · p.16Quality unit oversightChapter 1Source file
PQRs were not being completed in a timely manner: – 9 PQRs were open that were more than 6 months overdue with some up to almost a year overdue. – At least 29 closed PQRs that had gone beyond the 3 month due date with a number over 6 months beyond their due date.MHRA2016 · p.16Quality unit oversightChapter 1Source file
There was no mechanism to ensure that changes to regulatory requirements were captured and the impact to the site considered.MHRA2016 · p.17Quality unit oversightChapter 1Source file
There was no formal system for the review, assessment and where appropriate, implementation of EU GMP updates.MHRA2016 · p.17Quality unit oversightChapter 1Source file
There was no formal system to review regulatory updates.MHRA2016 · p.17Quality unit oversightChapter 1Source file
The returns procedure did not require verification that the returned goods had been stored under appropriate temperature conditions by the customer prior to the return.MHRA2016 · p.18Stability and storageChapter 1Source file
The production operative was signed off as trained in raw material assessment based on read and understand questionnaire with no practical assessment.MHRA2016 · p.20Material and supplier controlChapter 2Source file
The production operative was signed off as competent for manufacture of solutions and suspensions had not completed training in all associated duties such as cleaning of compounding equipment.MHRA2016 · p.20Equipment and facilityChapter 2Source file
Procedure awareness assessment forms were not all signed off by the trainer as required by the training procedure.MHRA2016 · p.20Training and personnelChapter 2Source file
There was no system for confirming that all personnel that required training had been trained.MHRA2016 · p.20Training and personnelChapter 2Source file
No evidence was seen for competency assessment for the GMP training of a recently recruited QA Officer.MHRA2016 · p.21Quality unit oversightChapter 2Source file
The training record of production operator did not show they were trained in the operation of the isolator despite being signed off for aseptic manufacturing.MHRA2016 · p.21Aseptic processing and sterility assuranceChapter 2Source file
There was no control to ensure that only trained contract cleaners enter the manufacturing facilities.MHRA2016 · p.21Equipment and facilityChapter 2Source file
There was no robust process for the monitoring of analyst training and qualification.MHRA2016 · p.21Validation and qualificationChapter 2Source file
When an analyst was qualified on one chromatography system, he was considered qualified on the other two systems used on site without any further competency checks performed related to understanding of differences between the systems.MHRA2016 · p.21Validation and qualificationChapter 2Source file
isolator gloves were creasedMHRA2016 · p.23Material and supplier controlChapter 3Source file
a bunch of plastic ties were pinned tightly togetherMHRA2016 · p.23Material and supplier controlChapter 3Source file
isolator gloves lying against product bagsMHRA2016 · p.23Material and supplier controlChapter 3Source file
small equipment such as scissors and spoons were lying horizontally on metal racking This would prevent effective sanitisation of the items.MHRA2016 · p.23Equipment and facilityChapter 3Source file
There had been no calculation of health based exposure limits or PDE values for the molecules used on site, and no assessment of the organisational or technical measures required within the production facilities.MHRA2016 · p.24Equipment and facilityChapter 3Source file
There was no drawing showing the pressure cascades within the facilities available.MHRA2016 · p.24Equipment and facilityChapter 3Source file
There was no documented assessment of the clean status of the product contact equipment, or the potential for contamination from product residues.MHRA2016 · p.24Cleaning validationChapter 3Source file
Equipment had not been cleaned beyond the standard approach for a product changeover.MHRA2016 · p.24Equipment and facilityChapter 3Source file
The warehouse was allowed to store mixed pallets of materials including same material, different lot numbers giving rise to the risk of mix up.MHRA2016 · p.25Material and supplier controlChapter 3Source file
There was no canopy over the goods-in / goods-out to provide cover whilst loading/unloading material.MHRA2016 · p.25Material and supplier controlChapter 3Source file
There was no demarcation between clean and dirty sides of the change room entering the formulation area.MHRA2016 · p.25Equipment and facilityChapter 3Source file
A pool of liquid was observed in the corner of the formulation area corridor, indicating poor maintenance (leak) or poor cleaning (spill) practices.MHRA2016 · p.25Equipment and facilityChapter 3Source file
Several clean sifting screens were stored together in a single plastic bag. It was confirmed that the bag was opened to remove a single screen for use, and then resealed with the potential risk of contamination of the other clean screens.MHRA2016 · p.26Equipment and facilityChapter 3Source file
There is no usage history of a sifting screen, such as the identity of the previous product in which it was used for manufacturing.MHRA2016 · p.26Equipment and facilityChapter 3Source file
The door seal on the coating machine was not intact and had sections missing.MHRA2016 · p.26Equipment and facilityChapter 3Source file
Equipment was not always being stored covered as required by procedure.MHRA2016 · p.26Equipment and facilityChapter 3Source file
Sticky tape was being used to hold the sight glass on to the tablet hopper on packing line.MHRA2016 · p.26Equipment and facilityChapter 3Source file
The temperature alarms within the manufacturing areas were set at 18°C to 26°C, yet some raw materials and finished products required storage between 2°C and 25°C. The site would thus not be notified of excursions between 25°C and 26°C.MHRA2016 · p.27Equipment and facilityChapter 3Source file
Temperatures and relative humidity were only captured twice per day throughout manufacturing as instantaneous measurements. No maximum/minimum data was available to provide assurance of temperature and relative humidity requirements at all times.MHRA2016 · p.27Equipment and facilityChapter 3Source file
The company had not assessed the methodology used by contractor to test HEPA filters within classified areas.MHRA2016 · p.28Equipment and facilityChapter 3Source file
There were no predetermined acceptance criteria documented for the external calibration activities including the warehouse temperature and humidity probes and the purified water flow meter.MHRA2016 · p.28Equipment and facilityChapter 3Source file
There was no requirement for a check of the delivery vehicle to ensure vehicles were suitable for transport of medicinal products/materials.MHRA2016 · p.28Material and supplier controlChapter 3Source file
Document retention policy was inconsistent e.g. the document control procedure identified that documents should be kept for the lifetime of the company, but the complaints procedure stated a retention period of 3 years for complaints.MHRA2016 · p.30Complaint and recall handlingChapter 4Source file
Non-contemporaneous recording was noted during placebo manufacture as the date completed for the process step on the batch production record had already been entered before that process step had actually been completed.MHRA2016 · p.30Documentation and recordsChapter 4Source file
The QC Preventive Maintenance and Calibration tracker had gaps and additions without appropriate explanation.MHRA2016 · p.30Equipment and facilityChapter 4Source file
A photocopy of a batch sheet page related to pallet stacking pattern seen in the trash container outside the bottle packing line was indication of an unacceptable practice of uncontrolled photocopying of pages of the batch record during use.MHRA2016 · p.31Documentation and recordsChapter 4Source file
There were no log books in place for each compounding workstation to ensure traceability of operations.MHRA2016 · p.31Documentation and recordsChapter 4Source file
Uncontrolled documentation was noted throughout: production engineering notebooks with set up details and passwords, crib notes on the wall of the goods in area, scraps of paper containing numbers of components brought onto line.MHRA2016 · p.31Material and supplier controlChapter 4Source file
Data integrity assessments were focused on system compliance and failed to consider the impact of business processes on the integrity of data, for example manual transfer of data between electronic systems.MHRA2016 · p.32Data integrityChapter 4Source file
The investigation relating to a data integrity failure, whereby fictitious utility monitoring data was recorded, lacked sufficient detail to demonstrate whether willful intent was suspected.MHRA2016 · p.32Data integrityChapter 4Source file
Printouts of particle count data from HEPA filter testing were not transferred from thermal paper to non-volatile media to ensure the integrity of the record throughout the retention period.MHRA2016 · p.32Equipment and facilityChapter 4Source file
The supplier qualification and audit procedure lacked sufficient definition of a critical material or supplier.MHRA2016 · p.34Material and supplier controlChapter 5Source file
Product containers were being over-labelled so GMP data was being obscured.MHRA2016 · p.34Material and supplier controlChapter 5Source file
The warehouse receiving area was not being temperature monitored so the acceptable temperature limit of <32°C could not be verified.MHRA2016 · p.34Material and supplier controlChapter 5Source file
Only the top layer of large dry powder chemical drums was being sampled so this material was not representative of the bulk material.MHRA2016 · p.34Material and supplier controlChapter 5Source file
API shipped from the supplier in India were not subject to temperature monitoring or control despite requiring storage at ≤25°C.MHRA2016 · p.35Material and supplier controlChapter 5Source file
The approved supplier list does not include the address of the manufacturer. The site is therefore unable to confirm that the material is received from both the correct supplier and manufacturer.MHRA2016 · p.35Material and supplier controlChapter 5Source file
There was no requirement to confirm that the tamper evident seal numbers were as expected upon receipt of APIs.MHRA2016 · p.35Other quality systemChapter 5Source file
There were no TSE certificates obtained for the reagents added to the purified water system.MHRA2016 · p.35Other quality systemChapter 5Source file
The warehouse receiving and unloading bays did not provide sufficient protection to materials during bad weather.MHRA2016 · p.35Material and supplier controlChapter 5Source file
No cleaning validation had been performed on the dispensing isolator.MHRA2016 · p.36Cleaning validationChapter 5Source file
The justification for not doing cleaning validation was weak and the risk mitigation factors considered in the associated risk assessment did not reflect actual practice.MHRA2016 · p.36Cleaning validationChapter 5Source file
There was no data to show that the cleaning of the mist shower was effective in removing any residual contamination.MHRA2016 · p.36Contamination controlChapter 5Source file
There was no diagram to show how drums would be loaded into the mist shower. This could lead to drums being packed to closely together which would create occluded surfaces which would not be wetted by the shower.MHRA2016 · p.36Contamination controlChapter 5Source file
There was no instruction to prevent the use of the raw materials dispensing booth whilst the dispensing isolator was being used.MHRA2016 · p.37Material and supplier controlChapter 5Source file
There were cracks in the vinyl around the mist shower drain. This would create a trap point which could cause the accumulation of chemical and microbial contamination.MHRA2016 · p.37Contamination controlChapter 5Source file
Equipment used to manufacture high potent materials was not verified as clean prior to removal to the general storage area.MHRA2016 · p.37Equipment and facilityChapter 5Source file
The FMEA risk assessment had failed to demonstrate adequate risk mitigation by referring to SOPs without detailing or assessing how controls were implemented.MHRA2016 · p.37Other quality systemChapter 5Source file
Where health based exposure limits were conducted, these had not been adequately integrated into the risk assessment process and the opportunities for retention in the equipment train at the ADE level had not been recorded in the context of the risk assessments.MHRA2016 · p.38Equipment and facilityChapter 5Source file
Cleaning failures identified at visual inspection by the second production inspector were not logged as deviations or similar to allow trending.MHRA2016 · p.38Deviation, CAPA, and investigationChapter 5Source file
There was no written instruction on rules of use of cleaning bays to ensure the risk of cross contamination between cleaned and un-cleaned items was controlled.MHRA2016 · p.38Contamination controlChapter 5Source file
There was no procedure to define how cleaning methods should be developed (i.e. by use of technical drawings and physical examination of the equipment) and verified to ensure a consistent approach was taken.MHRA2016 · p.39Equipment and facilityChapter 5Source file
The new product introduction procedure required products to be banded but not subject to development of health based exposure limits (PDE’s) and hazard assessments although it was acknowledged by the inspector that these had been generated for some products.MHRA2016 · p.39Other quality systemChapter 5Source file
Different labels were not adequately segregated in the labels store in the packaging site as multiple different labels were stored in the same location.MHRA2016 · p.40Labeling and packagingChapter 5Source file
Capsule shells are not stored at the manufacturer’s recommended humidity conditions (35 - 65%RH) in the warehouse.MHRA2016 · p.40Stability and storageChapter 5Source file
The sample receipt logbook in the QC laboratory was completed when a test request was received and not when the sample was received into the laboratory which could occur several days later, therefore sample traceability was not maintained and the data entry was not contemporaneous.MHRA2016 · p.42Laboratory and QC controlsChapter 6Source file
One of the stability chambers was poorly labelled with the incorrect temperature and relative humidity.MHRA2016 · p.42Laboratory and QC controlsChapter 6Source file
Clean glassware was not covered to prevent recontamination and a clean expiry date had not been defined.MHRA2016 · p.42Laboratory and QC controlsChapter 6Source file
Grade B glassware was used in the laboratory for GMP testing.MHRA2016 · p.42Laboratory and QC controlsChapter 6Source file
The Microbiology laboratory did not have a microbiological plate reader with magnifying glass to ensure an accurate colony count.MHRA2016 · p.42Laboratory and QC controlsChapter 6Source file
There was no justification for the twelve month expiry assigned to reagents.MHRA2016 · p.43Laboratory and QC controlsChapter 6Source file
There was no consideration of the chemical stability of the reagents when setting the shelf life for the opened chemicals.MHRA2016 · p.43Stability and storageChapter 6Source file
The mobile phase expiry period of 2 months for aqueous solutions could not be supported with data.MHRA2016 · p.43Laboratory and QC controlsChapter 6Source file
The risk to product was not minimised as the laboratory balances were on an annual calibration and they were only challenged with a single weight once a week.MHRA2016 · p.43Laboratory and QC controlsChapter 6Source file
There was only weekly checking of the temperature of the standards fridge and the probe had no maximum/minimum read outs.MHRA2016 · p.43Stability and storageChapter 6Source file
The laboratory incident report (LIR) for bulk product that failed moisture analysis by titration was re-sampled as part of the Phase II investigation without first re-testing the original sample or proving beyond reasonable doubt that it had been compromised. The agreed retest plan included the equivalent sample already taken for Hardness and Friability (H&F) as part of hypothesis testing. The H&F and re-sample passed and the OOS was overturned, however the LIR did also not record how the re-sample was to be conducted and record of resampling suggested the sample was not taken representatively from the run. Thus overall there remained an element of doubt over whether the batch homogeneity was adequate.MHRA2016 · p.44Deviation, CAPA, and investigationChapter 6Source file
The laboratory incident report (LIR) for an unknown impurity failure on batch 123 of API XYZ was re-sampled in support of the phase II investigation without first establishing adequate evidence to determine that the original sample had been contaminated. The re-sample testing was not included in the LIR report and there was no comment to explain what had been done with the re-sample.MHRA2016 · p.45Deviation, CAPA, and investigationChapter 6Source file
An OOS result was averaged with two in-spec results to generate a passing result.MHRA2016 · p.46Laboratory and QC controlsChapter 6Source file
Where re-sampling and re-testing was to be carried out, a maximum of three sets of analyses was permitted. This number of retests was not deemed to be statistically significant.MHRA2016 · p.46Laboratory and QC controlsChapter 6Source file
The Out of Specification procedure did not contain adequate controls relating to the resampling of material.MHRA2016 · p.46Material and supplier controlChapter 6Source file
There was no requirement for an investigation to be conducted by Manufacturing to identify potential contributory factors.MHRA2016 · p.46Deviation, CAPA, and investigationChapter 6Source file
Investigations did not include hypothesis for test failure before retesting.MHRA2016 · p.47Deviation, CAPA, and investigationChapter 6Source file
Investigations which identified laboratory error did not always include preventative actions to ensure that the same laboratory error would be avoided in future.MHRA2016 · p.47Deviation, CAPA, and investigationChapter 6Source file
There had been numerous stability failures (including pre- shelf life expiry) identified but these had not been formally assessed by the QPs or the impact on continued certification considered.MHRA2016 · p.48Stability and storageChapter 6Source file
The contract manufacturer did not notify the stability failures to the Marketing Authorisation Holders.MHRA2016 · p.48Stability and storageChapter 6Source file
There was no procedure in place for the management of critical service suppliers and there was no mechanism in place to enable the qualification and monitoring of supplier performance.MHRA2016 · p.50Material and supplier controlChapter 7Source file
There was no evidence of a review by company personnel of the audit report conducted by a third party auditor.MHRA2016 · p.50Training and personnelChapter 7Source file
There was no procedures that describe the training and competency assessment required for company auditors.MHRA2016 · p.50Training and personnelChapter 7Source file
Procedures did not describe the basis for accepting an audit report prepared by a third party.MHRA2016 · p.50Material and supplier controlChapter 7Source file
The technical agreement between Company A and Company B was insufficiently detailed. It only contained a series of bullet points covering Company B’s activities, and did not describe the responsibilities of Company A.MHRA2016 · p.51Material and supplier controlChapter 7Source file
The technical agreement between Company A and Company C contained conflicting statements regarding the responsibility for customer verification.MHRA2016 · p.51Material and supplier controlChapter 7Source file
The technical agreement with Company D did not identify the products that were to be within the scope of the agreement.MHRA2016 · p.51Material and supplier controlChapter 7Source file
The technical agreement with Company E did not identify which party was the Contract Acceptor and which was the Contract Giver. Additionally there was no explicit requirement for temperature monitoring devices to be used for shipment of goods to Company F.MHRA2016 · p.51Stability and storageChapter 7Source file
There was no consideration of whether the complaint referred to a falsified medicine.MHRA2016 · p.53Complaint and recall handlingChapter 8Source file
There was no requirement to obtain the product implicated by the complaint.MHRA2016 · p.53Complaint and recall handlingChapter 8Source file
There was no requirement to consider if any other batches were implicated.MHRA2016 · p.53Complaint and recall handlingChapter 8Source file
The complaint process did not require a check to consider if complaints were due to counterfeits.MHRA2016 · p.53Complaint and recall handlingChapter 8Source file
The procedure did not include contact details for the Defective Medicines Report Centre (DMRC) or requirements for the reporting of potential falsified medicines.MHRA2016 · p.53Complaint and recall handlingChapter 8Source file
Inadequate investigation was performed on site. For example, not reviewing manufacturing and other data available and also not considering the wider implications of the complaint on other batches.MHRA2016 · p.54Complaint and recall handlingChapter 8Source file
Complaint investigations were not always documented contemporaneously.MHRA2016 · p.54Complaint and recall handlingChapter 8Source file
Due to the lack of site investigation, CAPA were not always considered or effective to prevent reoccurrence.MHRA2016 · p.54Deviation, CAPA, and investigationChapter 8Source file
The recall procedure did not define maximum timelines for key steps to ensure the recall process was completed in a timely fashion.MHRA2016 · p.55Complaint and recall handlingChapter 8Source file
There is no requirement to perform an out of normal working hour test of the recall system.MHRA2016 · p.55Complaint and recall handlingChapter 8Source file
The mock recall challenge was not completed in a timely manner and no final formal assessment report was generated.MHRA2016 · p.55Complaint and recall handlingChapter 8Source file
There is no procedural instruction to ensure that any in-house stocks of product potentially affected by a recall are quarantined.MHRA2016 · p.55Complaint and recall handlingChapter 8Source file
The mock recall process did not effectively challenge the supply chain and did not require a reconciliation or report to consider the effectiveness of the recall.MHRA2016 · p.55Complaint and recall handlingChapter 8Source file
Although two self-inspections had been performed these had not covered key aspects of the Quality Systems.MHRA2016 · p.57Quality unit oversightChapter 9Source file
There was no self-inspection schedule in place.MHRA2016 · p.57Quality unit oversightChapter 9Source file
Bags containing filling equipment (for example filling needles) were opened by tearing the bag which presented a risk of introducing fibres to the equipment/line and subsequently the product.MHRA2016 · p.59Aseptic processing and sterility assuranceAnnex 1Source file
The innermost bag containing the stopper track was damaged prior to loading into the filling line which presented a risk of fibres being transferred to stoppers and subsequently the product.MHRA2016 · p.59Aseptic processing and sterility assuranceAnnex 1Source file
There was insufficient evidence documented to demonstrate that the number of aseptic connections after sterilisation had been minimised.MHRA2016 · p.59Aseptic processing and sterility assuranceAnnex 1Source file
There is no sanitisation of hands after each individual garment is touched and put on.MHRA2016 · p.59Aseptic processing and sterility assuranceAnnex 1Source file
Operators wore outdoor clothes under aseptic gowns in the Grade B zone.MHRA2016 · p.60Aseptic processing and sterility assuranceAnnex 1Source file
Gowning procedures required operators to remove their shoes when entering grade D and C areas. The nature of the foot coverings used would not prevent microbial contamination passing from the operator’s feet onto the clean room floors.MHRA2016 · p.60Environmental monitoringAnnex 1Source file
In the main office of Block B manufacturing operators appeared to be allowed to wear flip flops, shoes with over-shoes or socks.MHRA2016 · p.60Training and personnelAnnex 1Source file
During gowning into the manufacturing area the bench was not sanitised prior to sitting on it.MHRA2016 · p.60Aseptic processing and sterility assuranceAnnex 1Source file
While donning sterile gloves prior to entering a grade B area an operator was observed touching the outside of sterile gloves on several occasions.MHRA2016 · p.60Aseptic processing and sterility assuranceAnnex 1Source file
Only the surfaces which are touched by the operator or are in contact with components on the compounder are sanitised before manufacture, rather than all surfaces as expected.MHRA2016 · p.61Material and supplier controlAnnex 1Source file
The hooks used for hanging bottles and bags were not cleaned appropriately as they were held together with the operator’s hand and sanitised as a group rather than individually to ensure that all surfaces are sanitised.MHRA2016 · p.61Training and personnelAnnex 1Source file
The wipes used for sanitisation did not appear to be wetted sufficiently as only the area in the centre appeared to be wet rather than the whole area to ensure effective surface coverage.MHRA2016 · p.61Aseptic processing and sterility assuranceAnnex 1Source file
A gap between the hood and mask was seen for some operators resulting in exposed skin at the side of the face with the potential for product contamination especially when working in a LAF cabinet.MHRA2016 · p.61Contamination controlAnnex 1Source file
There are currently no drawings or diagrams which define the positioning of components in the laminar air flow (LAF) cabinet or isolators to ensure that unidirectional airflow is maintained.MHRA2016 · p.62Material and supplier controlAnnex 1Source file
Operators do not wear goggles even though compounding is conducted in an open LAF cabinet and ampoules may be used in the compounding process which is an open rather than a closed manipulation.MHRA2016 · p.62Training and personnelAnnex 1Source file
Sanitised rather than sterile googles were permitted to be worn in EU Grade B areas.MHRA2016 · p.62Aseptic processing and sterility assuranceAnnex 1Source file
The sequence of installing the filling needles and connecting tubing did not minimise contamination risks; the sequence used resulted in contact between fingers of the restricted access barrier system (RABS) glove and the exposed tops of needles on several occasions.MHRA2016 · p.62Contamination controlAnnex 1Source file
The investigation into the media fill failure did not include a full chronology of events and did not include full details of all the corrective actions taken at each event. e.g. operator assessments, re-training of operators.MHRA2016 · p.63Aseptic processing and sterility assuranceAnnex 1Source file
A sample of the contaminated bag was not kept and therefore the contaminating organism was not able to be identified to species level which would have aided any investigation.MHRA2016 · p.63Aseptic processing and sterility assuranceAnnex 1Source file
The media fill batch size was 60 bags, however these were not labelled in the order of filling and therefore the position of the contaminated container could not be determined.MHRA2016 · p.63Aseptic processing and sterility assuranceAnnex 1Source file
The media fill and process validation studies did not capture the full complexity of the aseptic manufacturing processes used and therefore did not closely imitate the production process and were not representative of worst case.MHRA2016 · p.63Aseptic processing and sterility assuranceAnnex 1Source file
Sanitisation contact times were not being monitored and the five minutes contact time for the sporicide was not as defined by the sanitising agent manufacturer or validated by the Company.MHRA2016 · p.65Contamination controlAnnex 2Source file
Building Management System alarm cables were not being unclipped to aid effective end of campaign cleaning.MHRA2016 · p.65Equipment and facilityAnnex 2Source file
Gowns worn in EU Grade B rooms were not sterile and skin was exposed as googles were not worn.MHRA2016 · p.65Aseptic processing and sterility assuranceAnnex 2Source file
Sterile gloves were not being worn by the operator sanitising materials into the transfer hatch to the EU Grade B area.MHRA2016 · p.65Aseptic processing and sterility assuranceAnnex 2Source file
Outdoor clothing was worn in EU Grade B areas.MHRA2016 · p.65Contamination controlAnnex 2Source file
Airlock doors were not either interlocked or a door open warning system installed.MHRA2016 · p.66Aseptic processing and sterility assuranceAnnex 2Source file
There was not a change lock between each individual air classification.MHRA2016 · p.66Aseptic processing and sterility assuranceAnnex 2Source file
There was no local alarm in EU Grade B rooms to indicate a failure in the air supply.MHRA2016 · p.66Aseptic processing and sterility assuranceAnnex 2Source file
Records of visual inspection of cleaned disassembled equipment were not retained to confirm they were clean and available for re-use.MHRA2016 · p.68Equipment and facilityAnnex 3Source file
The risk assessment conducted prior to the inspection on suitability of organisational and technical measures in limiting risk of cross contamination did not apply an adequate challenge of current controls to confirm suitability or identify potential failure opportunities in the controls.MHRA2016 · p.68Contamination controlAnnex 3Source file
New equipment had not been fully and adequately assessed for design and construction and the required disassembly for cleaning purposes.MHRA2016 · p.68Equipment and facilityAnnex 3Source file
There was no procedural requirement for how cleaning and disassembly of equipment should be developed.MHRA2016 · p.69Equipment and facilityAnnex 3Source file
There was no record of failures seen at visual inspection stage that could be tracked for trend and validation review purposes.MHRA2016 · p.69Validation and qualificationAnnex 3Source file
There was a large powder deposit in the wash bay floor at the clean equipment out door that was attributed by site personnel to be product X. Gross clean should have been completed prior to equipment reaching the washroom so this appeared to indicate a breach of required practice. Additionally, a washroom should not be left with gross contamination.MHRA2016 · p.69Equipment and facilityAnnex 3Source file
Neither the authorised Quality Controller or Qualified Person detected that an OOS result had been recorded and this was only picked-up during preparation of the Product Quality Review.MHRA2016 · p.73Validation and qualificationAnnex 6Source file
An assumed root cause of human error was assigned however no attempt was made to verify this.MHRA2016 · p.73Stability and storageAnnex 6Source file
No consideration was given to informing the competent authority (via the Defective Medicines Reporting Centre) of the potential risk of defective product being on the market.MHRA2016 · p.73Stability and storageAnnex 6Source file
Filled medical oxygen Dewars were not stored under cover in a manner that ensured that they would be delivered in a clean state, compatible with the environment in which they will be used.MHRA2016 · p.74Annex 6Source file
Product labels on filled Dewars, available for despatch, were defaced such that registered details were not always fully visible.MHRA2016 · p.74Labeling and packagingAnnex 6Source file
The current process for filling tankers did not ensure a prospective independent quality (QC or QP) release prior to delivery to customers or a QP certification.MHRA2016 · p.74Annex 6Source file
The justification for the lack of residual pressure check on incoming Dewars had not been documented and the validation report for the purging process was not available on site and therefore could not be inspected.MHRA2016 · p.74Validation and qualificationAnnex 6Source file
Sampling plans for printed packaging components were not statistically based.MHRA2016 · p.77Material and supplier controlAnnex 8Source file
There is no designated sampling location for printed packaging materials; instead they are sampled on the storage pallets in the warehouse.MHRA2016 · p.77Material and supplier controlAnnex 8Source file
Sampling of printed packaging components did not take account of the production method in that there was no requirement to ensure all printing stations from the component printing company were included in the sample.MHRA2016 · p.77Material and supplier controlAnnex 8Source file
Shade cards used for checking printed packaging components were not adequately controlled in that there were no checks performed against a reference standard (e.g. pantone chart).MHRA2016 · p.77Material and supplier controlAnnex 8Source file
It could not be confirmed that the validated manufacturing process was routinely achieved, as the mixer in manufacturing room 5 was not calibrated and the speed was not routinely verified.MHRA2016 · p.79Annex 9Source file
Following a software update, data was lost from an autoclave control system. The system backup was unable to recover lost data as the backup was only performed on a 3 monthly basis.MHRA2016 · p.82Computer system validationAnnex 11Source file
The backup CD/DVD for the autoclave control system was not stored within a controlled environment to assure its integrity.MHRA2016 · p.82Computer system validationAnnex 11Source file
Data from the integrity test was not backed up. The system was observed to overwrite previous data.MHRA2016 · p.82Computer system validationAnnex 11Source file
Backups were required to be reviewed for accessibility annually for 5 years however this failed to ensure that data that is required to be stored for longer such as validation data, was accessible for its full retention period.MHRA2016 · p.82Computer system validationAnnex 11Source file
Backups were permitted to be made on the same computer drive which failed to ensure that a separate copy was available following drive failure or corruption.MHRA2016 · p.82Computer system validationAnnex 11Source file
Access to files and the system clock on the hard drive were available to all users.MHRA2016 · p.83Computer system validationAnnex 11Source file
The lock screen used a shared password. If a user had logged into the software behind the lock screen and another user opened the computer, they could perform actions under the initial user’s login.MHRA2016 · p.83Computer system validationAnnex 11Source file
Users had more authorisation on the chromatography data system than was permitted according to the SOP.MHRA2016 · p.83Computer system validationAnnex 11Source file
Access control systems were not considered GMP systems despite their intended purpose to control access to GMP areas.MHRA2016 · p.83Computer system validationAnnex 11Source file
Unique user passwords were not enforced.MHRA2016 · p.84Laboratory and QC controlsAnnex 11Source file
Users were permitted to change the default audit trail.MHRA2016 · p.84Data integrityAnnex 11Source file
Users were permitted to change the default “require user comments”.MHRA2016 · p.84Laboratory and QC controlsAnnex 11Source file
Users were permitted to copy non-related projects.MHRA2016 · p.84Laboratory and QC controlsAnnex 11Source file
Users were permitted to use annotation tools.MHRA2016 · p.84Laboratory and QC controlsAnnex 11Source file
Dosimeters could be reread and individual thicknesses be input into the shared-arm dipole array (SADA) system if a variation of 6% was identified for a location, this did not result in a deviation to review the validity of previous acceptable resultsMHRA2016 · p.86Deviation, CAPA, and investigationAnnex 12Source file
New thickness readings resulting from the scenario had no second person verification to ensure accuracy of the data used.MHRA2016 · p.86Annex 12Source file
It was unclear which party was responsible for issuance of the QP Declaration for import for comparator products sourced from non-EU countries.MHRA2016 · p.88Labeling and packagingAnnex 13Source file
A declaration had not been issued for product recently imported and certified for further processing despite this being a requirement within the respective Technical Agreement.MHRA2016 · p.88Labeling and packagingAnnex 13Source file
The PSF was inadequate as it did not include a summary reference to all documents associated with the clinical trial and current version numbers. The current document ‘manufactured product specification’ which is called the PSF is not appropriate.MHRA2016 · p.89Labeling and packagingAnnex 13Source file
The investigational medicinal product dossier (IMPD) states that plastic vials from Country F should only be used however, vials from another site in Country G are also used.MHRA2016 · p.89Labeling and packagingAnnex 13Source file
The IMPD was not updated following the initial rejection of the Clinical Trial application and subsequent changes to the specification and process.MHRA2016 · p.89Labeling and packagingAnnex 13Source file
There was no change control or overall project plan in relation to the acquisition of the existing site, equipment and materials. There was no user requirement specification (URS) for the A facility, in contrast to the L facility.MHRA2016 · p.92Equipment and facilityAnnex 15Source file
The L facility URS was inaccurate, for example with regard to the number and capacity of manufacturing vessels.MHRA2016 · p.92Equipment and facilityAnnex 15Source file
The re-qualification of the L facility purified water system highlighted two potential action items during the installation and operation qualification reviews. These items were not addressed in the subsequent performance qualification exercise, and were not captured elsewhere in the PQS.MHRA2016 · p.92Equipment and facilityAnnex 15Source file
The Validation Master Plan did not cover all required high level aspects and validation of utilities, process validation and cleaning validation were not considered.MHRA2016 · p.93Cleaning validationAnnex 15Source file
There was no routine re-validation of manufacturing processes.MHRA2016 · p.93Validation and qualificationAnnex 15Source file
There was no cleaning validation for the non-dedicated sampling tools.MHRA2016 · p.93Cleaning validationAnnex 15Source file
The method used for isolator leak tests during validation and requalification would not detect leaks.MHRA2016 · p.93Validation and qualificationAnnex 15Source file
Batch processing parameter ranges were not always supported by process validation data, for example the coating flow rate and the granulation chopper speed.MHRA2016 · p.93Process validationAnnex 15Source file
There is no clear indication in the process validation protocol that validation batches are predefined as potentially releasable for commercial sale.MHRA2016 · p.93Process validationAnnex 15Source file
Procedures permitted samples to be taken in the third country for EU QC testing; there was no requirement for a technical justification for this approach, nor any requirement to take periodic samples of the imported product to verify that samples taken in the third country were representative.MHRA2016 · p.95Quality unit oversightAnnex 16Source file
Arrangements for temperature monitoring of air shipments did not justify why data loggers were not required in every pallet.MHRA2016 · p.95Stability and storageAnnex 16Source file
Procedures allowed mean kinetic temperature (MKT) to be used to assess temperature excursions but did not require an investigation to be performed into the cause of the excursion.MHRA2016 · p.95Deviation, CAPA, and investigationAnnex 16Source file
Several products were routinely imported into the EU from the USA and stored at site for onward export to other third countries, however these were not subject to QP certification before being released for this export supply.MHRA2016 · p.96Quality unit oversightAnnex 16Source file
For those batches recognised as imported, there were no provisions implemented for random periodic analysis of samples taken after importation to justify ongoing reliance on samples taken in third countries.MHRA2016 · p.96Quality unit oversightAnnex 16Source file
The company did not hold any information with regards to the MA for the product which was released under the company MIA.MHRA2016 · p.97Quality unit oversightAnnex 16Source file
The company did not hold any information regarding confirmation of the supply chain.MHRA2016 · p.97Quality unit oversightAnnex 16Source file
There was no detail on the process and management of QP certification.MHRA2016 · p.97Quality unit oversightAnnex 16Source file
The release certification was not documented on company headed paper and did not include all details as per the Mutual recognition Agreement on the content of batch certificate.MHRA2016 · p.97Quality unit oversightAnnex 16Source file
No details of any Certificate of Analysis were held on file.MHRA2016 · p.97Quality unit oversightAnnex 16Source file
The QP did not ensure that he had current knowledge of the company PQS.MHRA2016 · p.97Quality unit oversightAnnex 16Source file
The arrangements associated with retention samples had not been fully defined.MHRA2016 · p.100Laboratory and QC controlsAnnex 19Source file
The training of aseptic area operators was significantly out of date for aseptic area validation activitiesMHRA2015 · p.7Aseptic processing and sterility assuranceChapter 1Source file
Annual competency checks for all relevant staff were also significantly out of dateMHRA2015 · p.7Quality unit oversightChapter 1Source file
Training record showed no GMP refresher training evidenceMHRA2015 · p.7Training and personnelChapter 1Source file
New technician started unsupervised manufacture but was not formally authorised to perform manufacture, indicative of a lack of control and invisible to product release staffMHRA2015 · p.7Quality unit oversightChapter 1Source file
There was no formal process on-site to ensure the updates to regulatory requirements were considered for impact on to the site quality system; for example Chapter 3, 5 and Annex 15MHRA2015 · p.8Quality unit oversightChapter 1Source file
There was no formal procedure to ensure that all updates to EU GMP were captured, reviewed and implementedMHRA2015 · p.8Quality unit oversightChapter 1Source file
The change control procedure did not include an appropriate process for effectiveness checksMHRA2015 · p.9Regulatory reporting and change controlChapter 1Source file
The change control form included a pre-populated statement of “approved changes have been implemented satisfactorily” and did not easily support any other commentMHRA2015 · p.9Regulatory reporting and change controlChapter 1Source file
Change controls were raised after projects were initiatedMHRA2015 · p.9Regulatory reporting and change controlChapter 1Source file
There was no evidence for completion of actions within the change control reports prior to closureMHRA2015 · p.9Regulatory reporting and change controlChapter 1Source file
The change control system had not been used in support of the change of use of production rooms/ workflowMHRA2015 · p.10Regulatory reporting and change controlChapter 1Source file
The Change Management SOP did not include formal post implementation review of changesMHRA2015 · p.10Quality unit oversightChapter 1Source file
The Change Control procedure did not include any requirement for appropriate effectiveness checks. The procedure did not refer or link to the Quality Risk Assessment SOP, and the requirement for risk assessments was unclearMHRA2015 · p.10Regulatory reporting and change controlChapter 1Source file
Change controls could be closed off before all implementation actions could be completedMHRA2015 · p.10Regulatory reporting and change controlChapter 1Source file
The nature of deviation was described incorrectly, as a result the quality impact of the deviation and CAPAs implemented were not appropriately assessedMHRA2015 · p.11Deviation, CAPA, and investigationChapter 1Source file
Complaints were not fully investigated as a result appropriate measures may not have been taken to prevent reoccurrenceMHRA2015 · p.11Complaint and recall handlingChapter 1Source file
Deviation investigations did not include an appropriate level of investigation and did not capture all relevant information Root cause was not always adequately considered. Example concluded a human error but did not consider that the error was influenced by the lack of a procedure to control the activity in question No process for assessing the effectiveness of the corrective / preventative actions to ensure that these are monitored and assessed, in line with Quality Risk Management principlesMHRA2015 · p.12Deviation, CAPA, and investigationChapter 1Source file
Deviation XX had recorded that personnel had been made aware of the issue to prevent recurrence pending full CAPA, however there was no evidence this had been done and the incident log indicated that a similar issue had occurred 5 days laterMHRA2015 · p.13Deviation, CAPA, and investigationChapter 1Source file
A lump seen in Product name batch XXX (reported in the batch releaser review) and passed to QC for investigation by Production was not recorded on batch documentation, in the incident log or as a deviation. As such there was no record of events at the time each action was taken. There had been no recorded measures to consider preventionMHRA2015 · p.13Deviation, CAPA, and investigationChapter 1Source file
There were no root causes identified and subsequently no actions taken to prevent any recurrenceMHRA2015 · p.14Aseptic processing and sterility assuranceChapter 1Source file
There has been nothing documented and no assessment performed to support continued manufacture and batch release of potentially affected productMHRA2015 · p.14Aseptic processing and sterility assuranceChapter 1Source file
There was no justification for the batches made at the same time and documentation to identify where the sterility test failures took placeMHRA2015 · p.14Aseptic processing and sterility assuranceChapter 1Source file
NCR-XX was raised for the Marketing Authorisation (MA) number being incorrect on cartons. Although this was picked up at the point of QP certification, there was no investigation into why the incoming material checks had not picked this up and also no corrective actions PDV–XX was raised as an incorrect MA number was printed on a packing specification. The investigation did not detail how the issue was identified. It also did not detail why it had occurred and what had been done to prevent reoccurrenceMHRA2015 · p.15Deviation, CAPA, and investigationChapter 1Source file
There was no job description for the Data Analyst and no training records to demonstrate appropriate training had been provided for the duties assigned to him There was no formal record of assessment of competence for GMP training The record showed that the training on the Deviation procedure had not been performed since July 2011, this had been to version 2 when version 3 had already been issued. The company were currently at version 5 with no evidence of training against the new updatesMHRA2015 · p.17Deviation, CAPA, and investigationChapter 2Source file
Vacancies in key production and QC analytical personnel had not been filled for extended periodsMHRA2015 · p.18Training and personnelChapter 2Source file
There were inadequate resources available to support the required improvements in the pharmaceutical quality system in parallel with introduction and qualification of the new facility as well as supporting routine production There was no process for, or record of, training in all procedure updatesMHRA2015 · p.18Equipment and facilityChapter 2Source file
Personnel had no documented training in the procedures or systemsMHRA2015 · p.19Training and personnelChapter 2Source file
The appropriate training for the QP and Managing Director was not clear as they were not identified within the training matrixMHRA2015 · p.19Training and personnelChapter 2Source file
Although comprehension questions were asked at the end of each module, there was no clearly defined pass mark therefore it could not be confirmed that the personnel understood the trainingMHRA2015 · p.19Training and personnelChapter 2Source file
There was no training and development plan in place for the staff member allocated to manage the non-conformance process to ensure adequately broad GDP awarenessMHRA2015 · p.19Training and personnelChapter 2Source file
The person checking returns had not been trained in the current procedure requirementsMHRA2015 · p.19Training and personnelChapter 2Source file
Retention sample storage area did not have a temperature logger in the vicinityMHRA2015 · p.21Equipment and facilityChapter 3Source file
The mapping of the production and warehousing areas performed by the contractor had not been approved by the companyMHRA2015 · p.21Equipment and facilityChapter 3Source file
The configuration of the drug storage room had changed with no assessment of the potential impact on the validity of the temperature mapping of the areaMHRA2015 · p.21Equipment and facilityChapter 3Source file
QC sampling of chemicals were performed in the material airlock in the pilot rooms. Room usage was not recorded and there was no record that the room was clean and clear prior to useMHRA2015 · p.22Material and supplier controlChapter 3Source file
QC sampling of packaging materials was not performed in a dedicated area in the Goods-in areaMHRA2015 · p.22Material and supplier controlChapter 3Source file
Areas of the facility and equipment were in a poor state of repair, e.g. damaged filter panel covers in the drying tunnel and damaged ventsMHRA2015 · p.22Equipment and facilityChapter 3Source file
The rubber seal within the dispensing equipment showed evidence of deterioration and sheddingMHRA2015 · p.22Laboratory and QC controlsChapter 3Source file
Pencil and tippex were present in the facilityMHRA2015 · p.24Equipment and facilityChapter 4Source file
Overwriting of hand recorded data and lack of adequate explanation for changesMHRA2015 · p.24Documentation and recordsChapter 4Source file
‘Post-it’ notes, loose note paper and hand-written notes on labels seen throughout the facilityMHRA2015 · p.24Equipment and facilityChapter 4Source file
Inappropriate changes made by obscuring data via fixing stickers over entries to amend the data recordedMHRA2015 · p.24Documentation and recordsChapter 4Source file
An uncontrolled, hand-written SOP for label printing was present in the printing area. This also included the system passwordMHRA2015 · p.24Labeling and packagingChapter 4Source file
Records were partially burnt or in waste bags awaiting destruction at the rear of the siteMHRA2015 · p.25Documentation and recordsChapter 4Source file
Included signed batch documentation, signed balance print outs, Certificates of Analysis and formally issued engineering record sheetsMHRA2015 · p.25Documentation and recordsChapter 4Source file
Some of the documents had been re-issued and completed retrospectively with the sanction of QAMHRA2015 · p.25Quality unit oversightChapter 4Source file
No explanation or record of the replication of dataMHRA2015 · p.25Documentation and recordsChapter 4Source file
There was no procedure for sessional visual checks of gloves on the isolatorMHRA2015 · p.26Documentation and recordsChapter 4Source file
Procedures and forms did not always reflect actual or required practiceMHRA2015 · p.26Documentation and recordsChapter 4Source file
Procedures were not always available or implemented adequatelyMHRA2015 · p.26Documentation and recordsChapter 4Source file
There was no documented check for the incoming condition of materials received to the storesMHRA2015 · p.26Material and supplier controlChapter 4Source file
New product introduction process did not consider the toxicity and potency risks to determine the need for any degree of dedicated facilityMHRA2015 · p.28Equipment and facilityChapter 5Source file
No formal process to define how organisational and technical measures should be developed and implemented to prevent cross contamination between productsMHRA2015 · p.28Contamination controlChapter 5Source file
No planned schedule for cleaning of the local extract and dust collection system in the compression roomMHRA2015 · p.28Contamination controlChapter 5Source file
A jug of cleaning liquid with a used cloth was found sitting on the capsule polishing unit that had been signed off as clean. The solution was said to be IPA but emitted a mal odour associated with microbiological contamination. The solution should have been discarded within 24 hours of make-up according to site procedureMHRA2015 · p.29Contamination controlChapter 5Source file
A ‘bulk’ container of IPA solution in the housekeeping store had a similar odour to the quantity found in the encapsulation roomMHRA2015 · p.29Other quality systemChapter 5Source file
The cleaning risk assessment did not consider the toxicity or potency of the materials being handled and was restricted to the difficulty of cleaningMHRA2015 · p.30Material and supplier controlChapter 5Source file
The automated tablet counter and tablet counting trays, which were used for multiple products, had not been considered as part of the cross contamination risk assessmentMHRA2015 · p.30Contamination controlChapter 5Source file
There was no confirmation that the cleaning methods would remove detergent residuesMHRA2015 · p.30Cleaning validationChapter 5Source file
The Active 1 and Active 2 API supplier had been approved without any evidence of audit of the facility. An EDQM certificate of suitability was on file for Active 1 however no certificate was on file for Active 2. The technical agreement with the company only cited Active 2 and did not include Active 1MHRA2015 · p.31Equipment and facilityChapter 5Source file
An audit of the HDPE bottle supplier had been performed; however no response to the audit was available. The technical agreement with the company was very brief, and did not include details such as TSE certification or labelling requirementsMHRA2015 · p.31Material and supplier controlChapter 5Source file
The approved vendor list observed in the secondary packaging warehouse did not include addresses for all suppliersMHRA2015 · p.31Material and supplier controlChapter 5Source file
The review failed to identify the atypically high Equilibrium Relative Humidity (ERH) at 36 and 48 month time points. The out of trend event was not reported and investigated. A risk assessment had not been performed on the products that were available on the marketMHRA2015 · p.33Stability and storageChapter 6Source file
An OOS result on appearance was reported at 30 month time point. No action was taken while there were products potentially available in the marketMHRA2015 · p.33Stability and storageChapter 6Source file
QC analytical records for the testing of Product X were deficient in that the IR spectra were missing from the data package and it could not be proven that a check of electronic data had taken place; the only recorded check being a tick on the front page of the data pack with the section on the Certificate of Analysis relating to IR ID testing being entirely blank. The test sheet for raw material X batch xxxxx was signed and checked as passed although it was still awaiting tests. The trend card associated with this material had also been completed ahead of results and checked.MHRA2015 · p.34Computer system validationChapter 6Source file
Glassware found within the main Chemistry laboratory was found to be stored wet pH meter electrodes located in the new microbiology laboratory had not been topped up with buffer storage solution so the pH probes had dried out Room temperature was not recorded or monitored in critical laboratory areas including the sample storage area and standard storage area The tests to ensure media was able to support microbial growth were not robust, for example there was no growth promotion test on each batch of media and there was no pH testing of mediaMHRA2015 · p.35Laboratory and QC controlsChapter 6Source file
There was no proceduralised assessment of the suitability of the Contract Acceptor to carry out the outsourced activitiesMHRA2015 · p.37Material and supplier controlChapter 7Source file
There had been no documented assessment of the suitability of Contract Acceptor A to carry out the relabeling activities for the parallel distributed productsMHRA2015 · p.37Material and supplier controlChapter 7Source file
The company had not reviewed or assessed the records and the results related to the outsourced activities to Contract Acceptor AMHRA2015 · p.37Material and supplier controlChapter 7Source file
Technical Agreements and audits were not in place for a number of suppliers The technical agreements had not been signed by the companies The technical agreement with Company X was contradictory in regard to the responsibility for assuring API compliance with EU GMP and TSE requirements There was no inventory of Technical Agreements (TAs) for outsourced activities and no review period Assessment of the competence of outsourced service providers was not always completedMHRA2015 · p.38Material and supplier controlChapter 7Source file
There had been several complaints for products failing to work and delivery failures in addition to several batches that had been previously rejected for delivery time and delivery volumeMHRA2015 · p.40Complaint and recall handlingChapter 8Source file
There had been no assessment as to the impact of these failures on the product on the market, specifically into the safety and efficacy of the productMHRA2015 · p.40Complaint and recall handlingChapter 8Source file
A complaint was received for batch ABC with regards to the product not working in July 2014. As a result of this, an investigation was raisedMHRA2015 · p.41Complaint and recall handlingChapter 8Source file
Retained samples were pulled and tested and were out of specification for dimensional testing. At the time this was assessed as no product impactMHRA2015 · p.41Complaint and recall handlingChapter 8Source file
The company had subsequently failed to consider this additional information whilst investigating the similar failures identified in stability tests and therefore did not make a robust product impact assessmentMHRA2015 · p.41Stability and storageChapter 8Source file
Missing out of hours check of the recall procedureMHRA2015 · p.42Complaint and recall handlingChapter 8Source file
No requirement to record the learning points of a recallMHRA2015 · p.42Complaint and recall handlingChapter 8Source file
The recall records did not contain any evidence of what occurred between receipt of the complaint on 25/11/15 and confirmation with DMRC on 1/12/15MHRA2015 · p.42Complaint and recall handlingChapter 8Source file
No written recall correspondence with customersMHRA2015 · p.42Complaint and recall handlingChapter 8Source file
Recall record xx-xx/xx did not contain a record of when the company assessed whether any stock was handled/supplied by company XMHRA2015 · p.42Complaint and recall handlingChapter 8Source file
Training of individuals carrying out self-inspection was limited to a review of the SOP and verbal discussion, no list of approved internal auditors was held confirming areas of competence The self-inspection SOP focused on the use of checklists without wider scope or guidance on assessment of responses There was no schedule in place for internal audits Self inspection has not been conducted since 2011MHRA2015 · p.44Training and personnelChapter 9Source file
There was no schedule for the self-inspections to be carried outMHRA2015 · p.45Quality unit oversightChapter 9Source file
Not all areas were covered by the self-inspectionsMHRA2015 · p.45Quality unit oversightChapter 9Source file
Actions from previous self-inspections were not confirmed as being completed and were not entered into any tracking systemMHRA2015 · p.45Quality unit oversightChapter 9Source file
Organisms associated with the continued environmental failures were only identified to genus level and not to species level with Staphylococcus and Bacillus commonly reportedMHRA2015 · p.47Aseptic processing and sterility assuranceAnnex 1Source file
There was no process to requalify personnel involved in sessions with gross microbiological monitoring failuresMHRA2015 · p.47Aseptic processing and sterility assuranceAnnex 1Source file
The spray and wipe technique demonstrated (although not a batch related sanitisation run) during the inspection was not adequate or conducted according to site procedure in that insufficient spray was applied and not all surfaces were wipedMHRA2015 · p.47Aseptic processing and sterility assuranceAnnex 1Source file
There had been no validation of the media fill method and no positive controls runMHRA2015 · p.47Aseptic processing and sterility assuranceAnnex 1Source file
The transfer of material across zones of different air classification was inadequate in that all sterile components are not kept in the grade A area at all times or alternatively protected via an outer layer of packaging removed before transfer into Grade AMHRA2015 · p.48Aseptic processing and sterility assuranceAnnex 1Source file
There is no indication that all components and supporting equipment or tools have been sterilised and the date of sterilisation written on the wrapping, nor the length of time the items have been held in the Grade B zoneMHRA2015 · p.48Aseptic processing and sterility assuranceAnnex 1Source file
Dedicated tooling required for interventions were not all sterilised into the Grade A environment for adjustments as needed (e.g. manifold tool), resulting in opening of panels unnecessarilyMHRA2015 · p.48Aseptic processing and sterility assuranceAnnex 1Source file
There were no settle plates located close to the point of fill to provide adequate assurance during exposure periods that EU GMP Annex 1 grade A limits were being metMHRA2015 · p.49Aseptic processing and sterility assuranceAnnex 1Source file
There were no settle plates located in the zone where samples were taken for IPC weight checksMHRA2015 · p.49Aseptic processing and sterility assuranceAnnex 1Source file
The continuous particle monitoring sample points were located too high in relation to the relevant work zones to provide meaningful data to demonstrate that EU GMP Annex 1 requirements were being metMHRA2015 · p.49Aseptic processing and sterility assuranceAnnex 1Source file
Not all phases of production were subject to microbial monitoring, e.g. activities with no cellular product present such as preparation of equipment, which has a similar potential for contamination of productMHRA2015 · p.51Environmental monitoringAnnex 2Source file
At decontamination of items for transfer into the isolator it was noted that not all areas of potential contact on the trolley were subject to decontaminationMHRA2015 · p.51Environmental monitoringAnnex 2Source file
The clean room was only monitored after cleaning. There was no periodic monitoring before cleaning to monitor for potential microbial changes or for the continuing effectiveness of cleaningMHRA2015 · p.51Environmental monitoringAnnex 2Source file
Maintenance activities on incubators in the global cell banking area did not include changing internal tubing on the humidification system at an appropriate frequency, so creating a potential biofilm generation riskMHRA2015 · p.52Environmental monitoringAnnex 2Source file
It was noted that particle counters and viable air monitoring samplers had been brought back into the microbiology laboratories from production areas without any consideration of the risk of contamination Materials were being stored in an area where the acceptable temperature range was outside the storage range defined by the kit manufacturer without a documented justification being in placeMHRA2015 · p.52Environmental monitoringAnnex 2Source file
The release statement on the batch in the dispatch area appeared to indicate that the product was packed and dispatched at 0645 which was before the formal QC release at 0655MHRA2015 · p.54Annex 3Source file
The release statement stated that the batch was ‘fit for human use’ rather than being manufactured to GMPMHRA2015 · p.54Annex 3Source file
The parameters in the production report to be reviewed at batch release were not formalisedMHRA2015 · p.54Annex 3Source file
Batch release does not include a review of either a printed or electronic copy of the synthesis recordMHRA2015 · p.55Annex 3Source file
Testing for residual solvents is not always performed as a pre-release test for all F18 products when there is adequate time to perform this test prior to releaseMHRA2015 · p.55Annex 3Source file
The instrument used for analysis of carbon monoxide was unavailable for an extended period. The company continued to manufacture and release batches during this period without any suitable justification (e.g. written risk assessment) for not performing the registered carbon monoxide testMHRA2015 · p.57Laboratory and QC controlsAnnex 6Source file
There was no requirement for periodic moisture analysis of medical oxygen batches or suitable justification for not doing soMHRA2015 · p.57Laboratory and QC controlsAnnex 6Source file
A pallet of empty cylinders was seen to be stored in the area designated for rejected oxygen/nitrous oxide starting material cylindersMHRA2015 · p.58Material and supplier controlAnnex 6Source file
Cylinders awaiting inspection in the workshop were not identified as such and were noted to be emptyMHRA2015 · p.58Annex 6Source file
The quarantine area in the workshop was not suitably delineated There was no system for confirming that returned cylinders had retained a positive pressure prior to refillingMHRA2015 · p.58Annex 6Source file
The checks in place to confirm that materials were received from an approved supplier were insufficient to confirm that the materials had been received from a specific address of each approved supplierMHRA2015 · p.60Material and supplier controlAnnex 7Source file
Samples of raw materials were only taken from the surface Sampling of APIs and high risk excipients did not require core representative sample to be taken Identification testing was not completed on each container of starting material There was no requirement to perform any incoming ID testing for development materials that were subsequently approved for use within the GMP areasMHRA2015 · p.62Material and supplier controlAnnex 8Source file
Risk management principles not applied throughout the lifecycle of computerised systems to determine the extent the validation and data integrity controls requiredMHRA2015 · p.64Data integrityAnnex 11Source file
Electronic data not used to check analytical resultsMHRA2015 · p.64Data integrityAnnex 11Source file
No control of user permissions on HPLC systems, e.g. no individual log-on and no separation of access levelsMHRA2015 · p.64Data integrityAnnex 11Source file
Setting within HPLC software not fully enabled e.g. audit trailMHRA2015 · p.64Data integrityAnnex 11Source file
Analyst had access to delete dataMHRA2015 · p.64Data integrityAnnex 11Source file
Manual integration was permitted routinely without additional review or permissionMHRA2015 · p.65Computer system validationAnnex 11Source file
The clock used for determining time/date for the HPLC software could be adjusted therefore allowing the option to alter the true time and date in the printed paper recordsMHRA2015 · p.65Computer system validationAnnex 11Source file
There were no audits to address the data integrity controls within the laboratory, data integrity was not included within the scope of audits of contact laboratoriesMHRA2015 · p.65Data integrityAnnex 11Source file
The list is not a current, accurate list and the GMP functionality of the systems is not included / apparentMHRA2015 · p.66Data integrityAnnex 11Source file
The access control system has been defined as not a GMP system and as a consequence has not been validated. The computer registration document states that this is not the system which controls entry to GMP areas. It is understood that there is no other system to control entry to GMP areasMHRA2015 · p.66Data integrityAnnex 11Source file
There was no formal process for controlling the reissue of labels in the event that these were required, in particular for labels including a patient numberMHRA2015 · p.68Labeling and packagingAnnex 13Source file
The procedure was not clear regarding the checks performed when labels were printedMHRA2015 · p.68Labeling and packagingAnnex 13Source file
Labels were printed from a ‘Master Template’ generated in MS Word which was fully editable at the time of printingMHRA2015 · p.68Labeling and packagingAnnex 13Source file
Batch ABCDE related to an expiry update operation however there was no formal QP certification of this, only a statement from the QP that the finished product had been previously certified, with no confirmation that the revised expiry date was acceptable under the provisions of the CTA Prior to the certification of aseptic batches manufactured in August 2014 there was a series of environmental failures and media fill failures. There was no formal mechanism for the QPs to be made aware of these events before the bimonthly product quality meeting that took place in September. It was therefore not clear that the QP had adequately assessed the impact of these events prior to certificationMHRA2015 · p.69Aseptic processing and sterility assuranceAnnex 13Source file
Not all new equipment qualification included the design phase of qualification e.g. Design Qualification or User Requirements Qualification documents provided by equipment suppliers were not adopted into the company’s Pharmaceutical Quality System to ensure appropriate review The heat tunnel equipment Operational Qualification was not fully complete with omissions noted Whilst the OQ protocol for the HVAC system was supplied by the third party, there was no evidence that the company had confirmed the suitability and compared that with the company procedures prior to approvalMHRA2015 · p.71Equipment and facilityAnnex 15Source file
The cleaning validation / verification was deficient and did not assure the effective removal of organic compoundsMHRA2015 · p.72Cleaning validationAnnex 15Source file
The effectiveness of sprayballs used for vessel cleaning have not been demonstrated or adequately controlledMHRA2015 · p.72Cleaning validationAnnex 15Source file
Permitted limits for carryover of organic molecules have not been set or adequately risk assessedMHRA2015 · p.72Cleaning validationAnnex 15Source file
Swab samples have not been taken, in particular no swabs have been taken from difficult to clean areas where other methods or determining residues may not be effectiveMHRA2015 · p.72Cleaning validationAnnex 15Source file
The cleaning of open vessels has not been verifiedMHRA2015 · p.72Cleaning validationAnnex 15Source file
Performance and Process validation activities did not include assessment of all critical parameters e.g. tablet dimensions and embossing Not all aspects of manufacturing were covered by process validation e.g. the use of the small coating pans as opposed to the validated automated system Batches of product were validated contemporaneously without justification for release prior to completion of the qualification process There was no clear scientific rationale to support the selection of products used for cleaning validation matrix or qualification limitsMHRA2015 · p.73Cleaning validationAnnex 15Source file
The Qualified Person did not have visibility of the Overall Risk Assessments which were used to manage the project and formed part of the change control process Product release certificates for a non-licensed product (for export) inappropriately referenced the MIA number and GMP certificate number, neither of which was applicable to this product. The statement also referenced compliance with local regulatory authority requirements that would not be applicable to the products in questionMHRA2015 · p.75Validation and qualificationAnnex 16Source file
The QP Batch Certification Checklist did not include a check that the Qualified Person had reviewed the Quality Impact Assessment and found it to be acceptable or otherwise for certification of the batch The QP named on the licence was not being used for batch release and was not keeping up to date with site systems and had not visited the site in approximately 2 yearsMHRA2015 · p.76Validation and qualificationAnnex 16Source file
A retained sample selected as an example could not be found during the inspection The stability protocol operating procedure did not ensure adequate reconciliation of the samples stored and used with a 5% reconciliation/tolerance limit in operation at the end of the stability programme There were no storage facilities, monitoring devices or associated procedures for the intended storage of the reference/retention samples at the siteMHRA2015 · p.78Equipment and facilityAnnex 19Source file
No deficiencies match.
No company names are given. The EU GMP chapter or annex follows the page heading in the report.
Not translated. Long sentences are shortened and link to the source file. As of 2026-11-10.
Source: Medicines and Healthcare products Regulatory Agency (MHRA), GOV.UK — Good manufacturing practice inspection deficiencies (https://www.gov.uk/government/statistics/good-manufacturing-practice-inspection-deficiencies). Used under the Open Government Licence v3.0. Open Government Licence v3.0
GRM excerpted and arranged the source text (long statements cut; area categories and filters added). It may differ from the original — always check the source file. This page was not made or reviewed by MHRA.
Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.
Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.
Click the confirmation button in the email. It's sent from GRM Solutions Brief. If you don't see it, check your spam folder.